Epidiolex vs Vimpat
Side-by-side cost comparison based on Medicare Part D data
Epidiolex
Cannabidiol
Manufactured by Jazz Pharmaceuticals
Vimpat
Lacosamide
Manufactured by UCB
Vimpat costs 85% less per claim than Epidiolex ($270.00 vs $1,839.00). A generic version of Vimpat is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Epidiolex | Vimpat |
|---|---|---|
| Avg Cost Per Claim | $1,839.00 | $270.00 |
| Total Medicare Spending | $456.0M | $876.0M |
| Total Beneficiaries | 28,000 | 398,000 |
| Total Claims | 248,000 | 3,240,000 |
| Annual Cost/Patient | $16,286.00 | $2,201.00 |
| Year-over-Year Change | +18.4% | +4.2% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Jazz Pharmaceuticals | UCB |
| Condition | Seizure/Epilepsy | Seizure/Epilepsy |
| Generic Name | Cannabidiol | Lacosamide |
Epidiolex vs Vimpat: What the Data Shows
Epidiolex (Cannabidiol) and Vimpat (Lacosamide) are both used to treat seizure/epilepsy. Based on Medicare Part D data, Vimpat costs $270.00 per claim, which is 85% less than Epidiolex at $1,839.00 per claim.
Medicare spent $456.0M on Epidiolex and $876.0M on Vimpat. In terms of patient reach, Vimpat serves more beneficiaries (398,000 vs 28,000).
Year-over-year spending changed +18.4% for Epidiolex and +4.2% for Vimpat. Epidiolex saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Vimpat is cheaper at $270.00 per claim, compared to $1,839.00 for Epidiolex. That makes Vimpat about 85% less expensive per claim based on Medicare Part D data.
Yes, both Epidiolex and Vimpat are used to treat seizure/epilepsy. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Cannabidiol and generic Lacosamide can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $456.0M on Epidiolex covering 28,000 beneficiaries, and $876.0M on Vimpat covering 398,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.